What does this research mean for the field?

BPL-003 (5-methoxy-N,N-dimethyltryptamine) leads to a rapid and sustained reduction in depression symptoms in patients with treatment-resistant depression (TRD). Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To evaluate the safety and effectiveness of BPL-003 in patients with treatment-resistant depression.

March 2, 2026Open Access

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression

Key Points

To evaluate the safety and effectiveness of BPL-003 in patients with treatment-resistant depression.
Conducted as an uncontrolled, open-label phase 2 trial
Administered BPL-003 intranasally to participants
Monitored changes in depression symptoms using the MADRS scale over 12 weeks
Confirmed safety profile of BPL-003 in treatment-resistant depression population
Observed rapid and sustained reduction in MADRS scores
Findings suggest potential benefits, warranting larger controlled trials

Abstract

Results confirmed the safety profile of BPL-003 in a TRD population. A rapid and sustained reduction in MADRS score was observed over 12 weeks, suggesting BPL-003 could be beneficial in TRD, warranting investigation in larger controlled trials.

A phase 2 uncontrolled, open-label study of intranasal BPL-003 (5-methoxy- N,N -dimethyltryptamine) in patients with treatment-resistant depression

Key Points

Abstract

Cite This Study